通过分子动力学辅助发现了新型固酶-5抑制剂,其向的是一个独特的囊
Weihao Luo1, Runduo Liu2, Xinlin Cai1
1School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China.
Molecules (Basel, Switzerland)
|February 13, 2025
概括
研究人员发现了针对独特口袋的新型固酶-5 (PDE5) 抑制剂. 一种化合物AI-898/12177002对PDE6具有很高的选择性,在勃起功能障碍和肺动脉高血压治疗中可能减少副作用.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 计算机化药物发现技术
背景情况:
- 固醇酶-5 (PDE5) 是勃起功能障碍和肺动脉高血压的关键治疗标.
- 现有的PDE5抑制剂往往缺乏特异性,导致由于PDE6.6的交叉抑制导致不良反应.
- 准PDE5独特的全囊为开发选择性抑制剂提供了一种策略.
研究的目的:
- 通过向全osteric口袋来发现新的,选择性的PDE5抑制剂.
- 为了识别比PDE6.6具有更好的特异性的化合物.
- 为开发具有减少副作用的PDE5抑制剂提供基础.
主要方法:
- 集成的虚拟选,包括药模拟,分子对接和分子动力学模拟.
- 具有约束力的自由能量计算,以评估抑制剂-标相互作用.
- 在体外酶测试以确定抑制活性和选择性.
主要成果:
- 从33种测试的化合物中确定了7种具有独特支架的新型PDE5抑制剂.
- 这些抑制剂显示出显著的PDE5抑制 (在10μM时超过50%).
- 化合物AI-898/12177002的IC50为1.6μM,对PDE6.的选择性超过10倍.
结论:
- 该研究成功地确定了向全囊的强效和选择性PDE5抑制剂.
- 化合物AI-898/12177002代表了开发更安全的PDE5向疗法的有希望的头.
- 这些发现支持全囊作为设计下一代PDE5抑制剂的可行策略.
相关概念视频
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Protein Kinases and Phosphatases
13.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.0K
Allosteric Regulation
57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127
Cooperative Allosteric Transitions
2.3K
2.3K


